raloxifene has been researched along with Hormone-Dependent Neoplasms in 1 studies
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rosati, RL | 1 |
| Da Silva Jardine, P | 1 |
| Cameron, KO | 1 |
| Thompson, DD | 1 |
| Ke, HZ | 1 |
| Toler, SM | 1 |
| Brown, TA | 1 |
| Pan, LC | 1 |
| Ebbinghaus, CF | 1 |
| Reinhold, AR | 1 |
| Elliott, NC | 1 |
| Newhouse, BN | 1 |
| Tjoa, CM | 1 |
| Sweetnam, PM | 1 |
| Cole, MJ | 1 |
| Arriola, MW | 1 |
| Gauthier, JW | 1 |
| Crawford, DT | 1 |
| Nickerson, DF | 1 |
| Pirie, CM | 1 |
| Qi, H | 1 |
| Simmons, HA | 1 |
| Tkalcevic, GT | 1 |
1 other study available for raloxifene and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene.
Topics: Administration, Oral; Animals; Biological Availability; Bone Density; Breast Neoplasms; Cell Divisio | 1998 |